lead us lower ep estim visibl
remain low strateg outlook new ceo still
ahead pull guidanc remain ew lower pt
disappoint result report disappoint noisi set
result ebitda organ sale miss consensu guidanc
pull bln new impair charg develop clearli
neg lower estim roughli
under-perform weaker outlook new ceo miguel patricio
address market first time sinc appoint day ago
visibl still low full strateg review ahead weak trend
pull fy guidanc maintain long term bearish fundament outlook
equal-weight rate given compress valuat lower
pt downward earn revis
number adj ep ahead
consensu estim ex bln impair charg y/i declin
ebitda pronounc expect ebitda miss consensu
back weak organ sale margin pressur suppli chain cost
commod inflat organ sale declin flattish
expect report revenu miss consensu declin
driven us organ sale mainli affect reduc
inventori level retail impact contribut point top line
pressur consolid point declin organ sale meanwhil gross
margin declin bp y/i ahead consensu bp suppli chain
cost pressur combin higher expect sg bp y/i
sale ebitda declin y/i bp margin contract
final bln impair charg driven combin goodwil
write-off lower forecast sever busi includ us refriger
emea east brazil latam export lower intang asset valuat
driven higher discount rate depress stock price
strateg outlook new ceo miguel patricio address market first
time sinc appoint day ago strateg plan still
formul board year plan crystal end
food unit state america
unless otherwis note metric base modelwar
base consensu methodolog
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
year share market earli miguel share broad view
compani futur key messag stood us option
tabl miguel comment board given full support
contempl path creat valu sharehold updat
given regard addit potenti asset sale portfolio may
evolv time must invest brand peopl
near term higher invest particularli media/advertis like come
re-alloc resourc shift money away less effici
outlook guidanc fulli withdrawn previous
manag guid ebitda bln vs newli revis estim
bln new manag wish distract short-term
target said color given gener trend expect
broadli speak manag expect top line trend improv price
initi late fulli place y/i comparison easier
ebitda declin deceler seem reason us revis
estim give ebitda declin vs
though ep like pressur higher effect tax rate
increas stock compens interest expens
develop file calendar day extens publish
form plan publish august
manag reiter quarterli dividend state
expect organ cash flow suffici maintain dividend
de-lever current level though expect immedi
drop full receipt proce canada asset sale
lower estim price remain ew lower pt
mainli due downward estim revis
reduc ebitda ep estim ebit
under-perform lower growth base weaker outlook
suppli chain cost pressur expect continu coupl risk
organ sale weak due retail inventori reduct dcf assumpt
remain unchang flattish sales/ebitda compound-annual-growth-rate wacc tgr
continu valu roughli forward ebitda pt revis
primarili driven lower estim revis
deriv base case scenario
growth acceler margin upsid bp top-line upsid us market
share gain int upsid drive organ sale compound-annual-growth-rate
bps/yr margin expans top-line leverag resumpt product
compound-annual-growth-rate post wacc tgr exit multipl strateg
premium consolid halo return
stabil follow expect ebitda declin
model stabil start ebitda compound-annual-growth-rate growth
outsid north america mostli off-set continu weak
wacc tgr exit multipl
top-line deceler margin pressur continu bp top-line downsid
linger us market share struggl drive organ sale
compound-annual-growth-rate margin declin bps/yr price pressur fix cost de-lever
higher reinvest drive ebitda compound-annual-growth-rate dcf input
revenue/ebitda compound-annual-growth-rate post wacc tgr exit
declin expect
price-driven rebound back posit
territori deep dive us
busi sale highlight
leverag low/no growth end market
reduc pl momentum
backdrop forecast organ
sale compound-annual-growth-rate toward bottom peer
expans drive profit margin
unsustain level believ margin
process reset
reason level see risk
wide ii advertis spend still well
histor level iii recent
expect margin compress
expect mainli driven gm
compress still leav core sg
wide gap peer
stock price under-perform
trade ev/ebitda discount low
k/gis/sjm/cag believ
appropri reflect bearish
risk achiev price
trend price environ increment
strateg potenti sector rotat
yoy chg sale
good sold
sale
yoy chg gp
sell gener adminstr expens
sg sale
yoy chg sg
oi sale
yoy chg oi
profit tax
yoy chg pbt
incom continu oper
incom attribut
yoy chg ni
incom attribut common
yoy chg adj ep
cash equival
s-t debt interest payabl
accumul comprehens incom loss
total liabil stockhold equiti
bridg gaap net incom
adjust reconcil net incom
depreci amort
defer compens stock compens
chang oper asset liabil effect
account payabl accru expens
net cash flow oper activ
flow invest activ
sale busi
purchas busi
net cash flow invest activ
flow financ activ
repurchas common share
issuanc common share
net cash flow financ activ
effect fx chang cash cash equival
cash equival begin year
net chang cash cash equival
cash equival end year
